Dana-Farber Cancer Institute's cancer therapy developer raised $182m in an upsized IPO where it floated above its range.

UT Southwestern-founded Taysha Gene Therapies surpassed its goal after underwriters bought additional shares.

The Washington State University neurological drug developer has gone public after issuing 12 million shares priced at $17 each.

OSU's kidney dialysis technology provider has added about $36m to close its initial public offering, its shares having more than doubled in price.

Small molecule drug developer C4 has fied for a $100m initial public offering, three months after the Dana-Farber Cancer Institute spinout raised a $170m round.

Exosome therapy developer Codiak Biosciences – based on research at Gothenburg and MD Anderson Cancer Center – has filed to raise up to $100m.

PMV Pharmaceuticals – built on foundational work at Princeton – will use some of the proceeds to complete phase 1 trials of its lead asset.

QuantaMatrix is targeting $17.80 to $22.30 per share under a regulation permitting a listing on the basis of growth and technology potential.

UT Southwestern-linked CNS disease drug developer Taysha has filed to raise up to $100m in an IPO, just weeks after its $96m series B.

The Jilin University-aligned OLED materials producer generated $168m in an IPO set to fund enhancements to its product range.